New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations [Yahoo! Finance]
Indivior PLC - Ordinary Shares (INDV)
Company Research
Source: Yahoo! Finance
Post-hoc analyses indicated the 300-mg monthly maintenance dose performed significantly better than the 100-mg monthly dose in participants reporting high-frequency fentanyl use. RICHMOND, Va. Dec. 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses of SUBLOCADE® (extended-release buprenorphine) rapidly reduced opioid use and improved opioid abstinence and were well tolerated, with no new safety signals in individuals with moderate-to-severe opioid use disorder (OUD). Participants across both dose groups experienced a rapid reduction in opioid use—from more than 43 instances per week at screening to fewer than three instances per week by week three—a decline maintained through week 38. Post-hoc analyses also identified a subset of individuals who may benefit from the higher 300-mg maintenance dose of exte
Show less
Read more
Impact Snapshot
Event Time:
INDV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INDV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INDV alerts
High impacting Indivior PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
INDV
News
- New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk PopulationsPR Newswire
- Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Indivior (NASDAQ:INDV) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- A Fresh Look at Indivior (INDV) Valuation Following Recent Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Indivior Concludes Legacy U.S. Department of Justice Matter [Yahoo! Finance]Yahoo! Finance
INDV
Earnings
- 10/30/25 - Beat
INDV
Sec Filings
- 12/18/25 - Form 8-K
- 12/15/25 - Form 8-K
- 12/10/25 - Form SCHEDULE
- INDV's page on the SEC website